|
||
| |||||||
|
The link between diabetes and erectile dysfunction Up until the latter part of the 20th century the pharmaceutical industry focused on the development of therapeutic intervention for conditions with high levels of mortality such as cardiovascular disease and cancer. This situation is gradually changing as "quality of life" issues are becoming more important. Hence, the drug development community is increasingly targeting conditions that are usually not directly life-threatening and only cause significant disability in extreme cases. Perhaps the best example of such "quality of life" conditions is erectile dysfunction. This condition affects 31% of men and hence the launch of Viagra in 1998 produced a blockbuster for Pfizer almost overnight, with sales reportedly totaling $1.5 billion in 2001. Erectile dysfunction continues to hold commercial promise and raising the profile of sexual dysfunctions has resulted in a second wave of pharmaceutical activity targeting female sexual dysfunction. To reflect the growing importance of "quality of life" issues LeadDiscovery has now launched a new focus section "Lifestyles" which will highlight advances in conditions such as erectile dysfunction, IBS and stress. This week we focus on links between diabetes and erectile dysfunction. The two conditions have long been linked, however in a recent study of a large cohort of diabetics, this link has been probed in detail. A study of over 31,000 men, aged 50 years or older, has revealed that duration of diabetes was positively associated with increased risk of erectile dysfunction relative to nondiabetic subjects. Patients with type 1 diabetes were more likely to suffer from erectile dysfunction than those suffering type 2 diabetes. The treatment of diabetes complications represents a growing priority and erectile dysfunction is emerging as one such complication. Our recent report identifies new targets for erectile dysfunction and places these in the context of diabetes. Erectile dysfunction and our report may therefore be of growing interest to those companies with a focus on diabetes. Entry date September, 2002 Adapted from Bacon et al, Diabetes Care 2002 Aug;25(8):1458-63
Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
| ||||||||
